Adalimumab (HumiraTM) is the first fully humanized monoclonal TNF-αantibody that antagonizes the effects of TNF-α. Its use has been found in the treatment of various rheumatologic disorders, namely rheumatoid arthritis,Crohn``s disease, and ankylosing spondylitis, as well as for various skin conditions such as psoriasis. As the use of this particular biologic agent is becoming more widespread, cutaneous adverse effects of the drug is now being reported at a steady rate. The authors herein report a case of 32 year-old female who presented with multiple psoriasiform eruptions on her trunk, back and lower extremities. She had a four-year history of ankylosing spondylitis,for which she was started on subcutaneous adalimumab injection monthly, three and a half years prior to her initial visit.